Science

What Science does

Science Corporation is a clinical-stage, vertically integrated medical technology company founded in 2021 and headquartered in Alameda, California, that develops brain-computer interface (BCI) and neuroengineering systems to address neurological and sensory disorders. Its flagship clinical product is the PRIMA Visual Prosthesis — a 2mm × 2mm × 30µm wireless subretinal photovoltaic implant paired with camera-equipped augmented-reality glasses, designed to restore central vision in patients with geographic atrophy from age-related macular degeneration (AMD). Beyond PRIMA, the company's pipeline includes the Biohybrid cortical sensor (first human implant performed at Yale New Haven Hospital in April 2026, combining stem-cell-derived neurons with electronics), the Vessel portable organ-perfusion program announced in December 2025, and a BCI Ecosystem platform that bundles the company's silicon (NYX 512 neural recording ASIC; LUX 2K/16K microLED driver chips), MEMS fabrication services (Science Foundry in Durham, North Carolina), Axon Probes, the SciFi wireless headstage, and Synapse/Nexus software with Python, TypeScript, and C++ client libraries. The technology is supported by a dedicated North Carolina semiconductor fab and operational offices in New York, Paris (La Science SAS), and Bonn.

The company monetizes through multiple streams: future sales of the PRIMA system (implant plus glasses) contingent on CE mark approval (decision expected mid-2026) and FDA approval; per-chip hardware sales of NYX/LUX ASICs at $100 per chip during a limited preview run; professional services revenue from Science Foundry's MEMS process development and wafer fabrication; and multi-year, multimillion-dollar Ecosystem licensing agreements that grant partners access to the full clinical-grade BCI stack, reducing their first-in-human trial cost from $75–100M to under $5M. Its primary customer segments are patients with advanced dry AMD/geographic atrophy, academic and research neuroscientists, BCI startups, and foundry/MEMS customers; the company is also building a clinical network of retinal surgeons and rehabilitation specialists across the US and Europe.

Science has demonstrated first-in-class clinical efficacy: in the PRIMAvera pivotal trial published in The New England Journal of Medicine, 84% of patients with advanced dry AMD regained the ability to read letters and words, and 80% achieved meaningful visual-acuity improvement, with an accompanying NEJM editorial calling PRIMA 'the first treatment to restore vision.' The company has FDA Breakthrough Device designation for PRIMA and a CE mark application pending. Science has raised approximately $490 million since founding across 2021, 2024, 2025, and 2026 financings, including an oversubscribed $230M Series C in March 2026 at a reported $1.25–1.5 billion post-money valuation, led by Lightspeed Venture Partners and Khosla Ventures with participation from Y Combinator, IQT, and Quiet Capital. The company employs approximately 150 people and operates as a privately held Delaware corporation with a wholly owned French affiliate, La Science SAS, handling EU operations.

Name

Science

Legal name

Science Corporation

Website

https://science.xyz

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Short description

Science Corporation is a clinical-stage, vertically integrated medical technology company that develops brain-computer interface systems — including the PRIMA retinal prosthesis, Biohybrid neural interfaces, the Vessel organ-perfusion program, and the Science Ecosystem BCI platform — to address neurological and sensory disorders for patients with conditions such as age-related macular degeneration.

Ownership category

akta.pro rank

Product category

Brain-Computer Interface Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Semiconductor and Other Electronic Component Manufacturing (3344), Semiconductor and Related Device Manufacturing (334413)

SIC

Semiconductors & Related Devices (3674), Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industries

Sensors, MEMS & Imaging ICs (HDAHAAAG), High-Voltage, Power Discretes & Modules (IGBT/MOSFET/SiC/GaN) (HDAHAAAK)

Keywords

• Brain-computer interfaces
• Neural engineering platforms
• Retinal prosthetics
• Neural recording chips
• MEMS fabrication services

Headquarters

HQ city

Alameda

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales (PRIMA): Future revenue from commercialization of the PRIMA wireless retinal implant system (implant + glasses) in Europe and US, contingent on CE mark approval (expected mid-2026) and FDA approval. Class III implantable medical device with per-unit hardware revenue and associated consumables/glasses revenue.
2. Chip Sales (NYX & LUX): Per-chip sales of NYX 512 neural recording ASICs and LUX 2K/16K microLED driver chips to academic, research, and commercial collaborators via Science Foundry; preview pricing of $100 per chip during limited preview run, with general-availability pricing to be released later.
3. Foundry / MEMS Fabrication Services: Revenue from MEMS process development, wafer fabrication, and neural engineering toolkit services offered via Science Foundry to external customers, including custom thin-film transistor processes for microLEDs.
4. Ecosystem Licensing & Partnerships: Multi-year, multimillion-dollar licensing agreements granting partners access to the Science BCI Ecosystem (clinical-grade neural recording technology stack), enabling them to develop BCI products for tinnitus, epilepsy, and other neurological disorders.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels8 records

Core offering

Science Corporation develops brain-computer interface (BCI) neuroengineering systems, anchored by the PRIMA wireless subretinal photovoltaic retinal prosthesis that restores central vision in patients with geographic atrophy from age-related macular degeneration. The company also offers a vertically integrated BCI Ecosystem platform — comprising the NYX 512 neural recording ASIC, LUX 2K/16K microLED driver chips, Axon neural probes, SciFi headstages, Synapse Protocol API, Nexus data toolkit, and Science Foundry MEMS fabrication services — sold to academic researchers and licensed to BCI partners, plus the Biohybrid neural interface program and the newly launched Vessel perfusion/organ preservation platform.

Product overview

Science Corporation is a clinical-stage, vertically integrated medical technology company that sells a portfolio of products organized around a core "Science BCI Ecosystem" platform rather than a single monolithic product. The Ecosystem bundles Science Foundry (MEMS/wafer fabrication services), Axon Probes (thin-film and silicon neural probes), the SciFi Headstage, the NYX 512 neural recording ASIC and LUX 2K/16K microLED driver chips, the Synapse Protocol standard API, and the Nexus software toolkit — together these are the building blocks Science uses internally and licenses to academic and commercial partners via multiyear Ecosystem agreements. Sitting on top of that platform are Science's clinical and pre-clinical offerings: the flagship PRIMA Visual Prosthesis (a wireless subretinal photovoltaic BCI for restoring vision in advanced dry AMD), the Biohybrid neural interface (a stem-cell-derived biological BCI in early human feasibility work), and the newly launched Vessel perfusion/organ preservation program. Science's portfolio thus pairs a defensible vertically integrated technology stack (chips, probes, software, fab) with patient-facing BCI and life-support therapies, plus foundry services that allow outside groups to develop and commercialize BCIs against the same stack.

Differentiator

Problem solved

Functional benefit

Brands

• PRIMA: PRIMA Visual Prosthesis — a wireless subretinal photovoltaic BCI implant paired with augmented-reality glasses to restore central vision in patients with geographic atrophy from age-related macular degeneration.
• Biohybrid
• Vessel
• NYX
• LUX
• SciFi Headstage
• Axon Probes
• Synapse
• Nexus
• Science Ecosystem
• Science Foundry

Products and services

• PRIMA Visual Prosthesis A 2mm x 2mm x 30µm wireless subretinal photovoltaic brain-computer interface implant paired with specialized camera glasses that project near-infrared light onto the chip. Designed to restore central vision in patients with geographic atrophy secondary to age-related macular degeneration; CE mark application pending in EU with launch expected later in 2026 and FDA approval process underway.
• Biohybrid Neural Interface A neural interface that uses stem-cell-derived (lab-grown) neurons seeded on a thin-film electrode array and engrafted into the brain so that axons and dendrites grow out and wire up to host tissue, creating a biological bridge between device and brain. First human implant performed at Yale New Haven Hospital in April 2026 with Dr. Murat Günel as Medical Director.
• Vessel Perfusion Technology Program Portable organ preservation/perfusion technology program intended to take perfusion from a bridge to a destination, supporting and extending life. Launched as a new pipeline program alongside the Series C funding in late 2025.
• Science BCI Ecosystem End-to-end clinical-grade neural engineering platform that bundles Science Foundry (MEMS fabrication), Axon Probes, SciFi Headstages, NYX/LUX chips, Synapse Protocol software, and the Nexus toolkit. Licensed via multi-year Ecosystem agreements to enable partners to run first-in-human BCI trials for under $5M (vs. $75–100M typical standalone cost).
• SciFi Headstage Headstage electronics that process, store, and transmit signals between probes and the network over WiFi, designed for neural stimulation and high-bandwidth data acquisition in research and clinical applications.
• Synapse Protocol Flexible, powerful standard API (with Python, TypeScript, and C++ client libraries) for programming, controlling, and reading data from Science's neural interface devices and chips. Part of the Science Ecosystem software stack.
• Nexus Advanced data and behavior toolkit for neural engineering — intuitive and comprehensive suite of tools to design, program, and run neuroscience experiments alongside the Synapse Protocol.
• Axon Probes (Thin Film Axon / Silicon Axon) Neural probes available in flexible thin-film form factor (ideal for conforming to complex geometries) and rigid, scalable silicon form factor. High-precision detection and stimulation of neural signals; integrated with the Science BCI Ecosystem.
• NYX 512 Neural Recording Chip Low-noise, low-power, mixed-signal programmable neural recording ASIC with 512 electrodes (256 fully differential "nixels"), 16-bit data path, input-referred noise as low as 4.5 µV rms, sampling up to 32 kHz, packaged in a 4mm x 4mm chip-scale WLCSP with Cu bumps. Designed for ultra-compact headstages and high-density MEA neural recording.
• LUX 2K MicroLED Driver Chip Active 2K-pixel microLED driver designed for optogenetic stimulation; 64x32 array, 1.33 mm x 1.33 mm die, frame rates from 25 fps to 2500 fps, programmed via 4-wire SPI.
• LUX 16K MicroLED Driver Chip Passive 16K-pixel microLED driver for optogenetic stimulation; 128x128 array with 7-bit per-pixel current-mode DACs, 2.7 mm x 2.4 mm die, supports micro-LED and OLED displays and multi-channel current-mode DAC applications.
• Science Foundry Vertically integrated manufacturing services offering MEMS process development and wafer fabrication plus neural engineering toolkit access. Includes thin-film transistor processes for optogenetic probes and GaN-based microLEDs, exposed via open Process Design Kits; supports commercial BCI collaborations.

Quantifiable outcome

• 84% of trial patients were able to reliably identify letters and read after PRIMA implantation at 12 months
• +3 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability9 records

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and flagship.

• Yale Medical School (Dr. Murat Günel)coreStrategic or Co-development Partner · 31 March 2026Murat Günel, MD appointed as Medical Director for Brain-Computer Interfaces and scientific adviser to lead US human trials for Science's biohybrid cortical sensor. Overseer of the early feasibility study at Yale New Haven Hospital for first biohybrid neural interface implant in a human patient.
• Neurosoft BioelectronicsflagshipStrategic or Co-development Partner · 20 February 2026Multi-year, multimillion-dollar BCI Ecosystem Partnership granting Neurosoft access to Science's full stack of clinical-grade neural recording tools. Neurosoft is the inaugural inductee in Science's Ecosystem program. The partnership enables Neurosoft to run first-in-human trials for under $5 million versus $75–100M typical standalone cost. Neurosoft is developing minimally invasive, fully implantable BCI systems for tinnitus, epilepsy, and other disorders.
• Pixium VisionflagshipOthers · 1 January 2024Science Corporation acquired the PRIMA retinal implant technology from Pixium Vision in 2024. Pixium is a French company that originally developed the photovoltaic retinal prosthesis technology.
• La Science SASflagshipOthersCorporate affiliate based in Paris, France; serves as EU representative under Article 27 of GDPR; controller of personal data for EU employment candidates; facilitates Patient Registry services.
• Stanford University (Prof. Daniel Palanker)flagshipStrategic or Co-development PartnerPRIMA wireless implant system is based on foundational research by Professor Daniel Palanker at Stanford University, a co-author of the NEJM-published PRIMAvera trial paper. Science Corporation manufactures the implant based on Palanker's photovoltaic retinal prosthesis research.
• University Hospital of Bonn (Prof. Frank Holz)flagshipImplementation/ SI/ Consulting PartnerScientific Coordinator and lead author of the PRIMA clinical trial. Professor Frank Holz directs clinical evaluation of the PRIMA system at the Department of Ophthalmology, University of Bonn, Germany.
• Moorfields Eye Hospital / UCLflagshipImplementation/ SI/ Consulting PartnerUK clinical trial partner for the PRIMAvera pivotal trial, leading the UK arm of the international multi-center clinical study that demonstrated restoration of reading vision in patients with geographic atrophy from dry AMD.

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

Emerging players

• BRAINCO: BCI company developing both invasive and non-invasive neural interface products for consumer, education, and medical applications. Comparable as a vertically-integrated BCI developer with chip, software, and application stack, though focused more on non-medical and educational use cases.
• Inbrain Neuroelectronics: Emerging Spanish BCI company developing graphene-based neural interfaces for neurological disorders including epilepsy and Parkinson's. Comparable as a clinical-stage BCI startup targeting similar neurological indications and a potential Ecosystem licensee.

Direct peers

• Synchron: Direct peer developing a vascular (stent-like) brain-computer interface that does not require open brain surgery. Synchron is further along in clinical trials for paralysis applications and represents the leading minimally-invasive BCI approach, directly competing with Science's portfolio for BCI partnerships and clinical adoption.
• Paradromics: Emerging BCI company building high-data-rate neural interfaces for speech and motor restoration. Comparable to Science in stage (clinical/pre-clinical) and BCI focus, and a potential Ecosystem licensee or competitor for the same clinical indications.
• Neuralink: The most direct competitor in implantable brain-computer interfaces. Neuralink develops penetrating electrode BCIs for paralysis and speech restoration, with substantially higher reported valuation and broader consumer awareness. Science's vertical integration and Biohybrid/Bioelectronic differentiation are positioned against Neuralink's rigid-electrode approach.
• Precision Neuroscience: BCI developer of a surface-array cortical interface (Layer 7) designed to be less invasive than penetrating electrodes. Comparable to Science's Biohybrid approach in attempting to balance signal quality with reduced tissue damage, and competes for similar clinical indications.

Broad incumbents

• Blackrock Neurotech: Established BCI incumbent with a long history of research-grade neural interfaces used in academic BrainGate consortium trials. Broader portfolio and incumbency in research markets position Blackrock as a competitor to Science's Foundry and academic Ecosystem channel.
• Cortexigent (formerly Second Sight Medical Products): Clinical-stage developer of visual prosthetics for blindness, including the Orion cortical visual prosthesis. Most directly comparable to Science's PRIMA in retinal/cortical vision restoration, and a competitor for the same geographic atrophy and blindness indications.

Regional players

• Pixium Vision: French company that originally developed the PRIMA photovoltaic retinal prosthesis technology Science acquired in 2024. Closely comparable in retinal prosthesis focus but now structurally linked via the 2024 acquisition, and active in EU markets Science is entering with PRIMA.

Others

• BrainGate Consortium: Academic research consortium pioneering intracortical BCIs for paralysis and communication. Not a direct commercial peer, but functions as an ecosystem participant and validator of BCI clinical viability, with relationships that overlap Science's academic Ecosystem and Foundry customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/watch?v=J_qTLT8kJPU
• LinkedInlinkedin.com/company/sciencecorporation

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Science